All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
On April 19, 2021, it was announced that the European Commission (EC) approved the use of isatuximab (Isa) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma (MM) who have had ≥1 prior therapy. This approval was based on the results of the phase III IKEMA trial (NCT03275285), which were previously reported on the Multiple Myeloma Hub. They showed a 47% reduction in the risk of disease progression or death with Isa-Kd compared with Kd alone (HR, 0.531; 99% CI, 0.318–0.889; p = 0.0007).1
This Isa-Kd combination recently received approval from the U.S. Food and Drug Administration (FDA) for a similar indication, given on March 31, 2021.
FDA approves isatuximab combined with carfilzomib and dexamethasone for the treatment of RRMM
On March 31, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of isatuximab (Isa) in combination with carfilzomib...
Patient outcomes in multiple myeloma refractory to CD38 monoclonal antibodies
This retrospective study identified patients with active MM who were refractory to daratumumab or isatuximab as a single-agent or in combination (index regimen).
Subscribe to get the best content related to multiple myeloma delivered to your inbox